Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 4Neoplasm Metastasis 2Mastocytosis, Systemic 2Systemic Mastocytosis With an Associated Hematologic Neoplasm 1Sarcoma 1Recurrence 1Neoplasm, Residual 1Melanoma 1Mastocytosis 1Lung Neoplasms 1Colorectal Neoplasms 1

Interventions

Doxorubicin 15pembrolizumab 12Surgical Procedures, Operative 8Cyclophosphamide 8Blood Specimen Collection 8Ifosfamide 7Gemcitabine 7Surveys and Questionnaires 6Nivolumab 6Trabectedin 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Drug Therapy 5atezolizumab 4Temozolomide 4Specimen Handling 4Radiation Dose Hypofractionation 4Biopsy 4pazopanib 3liposomal doxorubicin 3fludarabine 3cabozantinib 3anlotinib 3Radiation 3Observation 3Docetaxel 3Dacarbazine 3trastuzumab deruxtecan 2toripalimab 2selinexor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Sarcoma × avapritinib × Clear all
NCT04771520 2026-03-02

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
DermatologicGastrointestinalSarcomaThoracic

Lung Neoplasms, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡